rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2014-10-5-540-547rpcardio-215Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯRATIONAL APPROACHES TO THE TREATMENT OF DYSLIPIDEMIA WITH DIFFERENT TOTAL CARDIOVASCULAR RISK AND ACUTE CORONARY SYNDROMEРАЦИОНАЛЬНЫЕ ПОДХОДЫ К НАЗНАЧЕНИЮ ЛЕЧЕНИЯ ДИСЛИПИДЕМИЙ ПРИ РАЗНОМ СУММАРНОМ РИСКЕ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ И ОСТРОМ КОРОНАРНОМ СИНДРОМЕПероваН. В.PerovaN. V.

д.м.н., профессор, в.н.с. отдела изучения биохимических маркеров риска хронических неинфекционных заболеваний

101990, Москва, Петроверигский пер., 10

Petroverigsky per. 10, Moscow, 101990 Russia

nperova@gnicpm.ruМетельскаяВ. А.MetelskayaV. A.

д.б.н., профессор, руководитель того же отдела

101990, Москва, Петроверигский пер., 10

Petroverigsky per. 10, Moscow, 101990 Russia

Государственный научно-исследовательский центр профилактической медициныРоссияState Research Centre for Preventive MedicineRussian Federation201424092015105540547Copyright © Perova N.V., Metelskaya V.A., 20152015Перова Н.В., Метельская В.А.Perova N.V., Metelskaya V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/215

Approaches to the total cardiovascular risk calculation based on the actual clinical recommendations are presented as well as the application of risk categories for the choice of strategy of dyslipidemia correction. The use of statins as lipid-lowering therapy in patients with acute coronary syndrome and coronary angioplasty are also discussed.

Изложены базирующиеся на современных рекомендациях подходы к расчету суммарного риска сердечно-сосудистых заболеваний и применению его величины для выбора тактики коррекции нарушений липидного обмена. Подробно рассмотрены вопросы применения в качестве липидснижающей терапии статинов при остром коронарном синдроме и коронарной ангиопластике.

дислипидемияхолестерин липопротеинов низкой плотностихолестерин липопротеинов высокой плотностирасчет суммарного риска сердечно-сосудистых заболеванийострый коронарный синдромdyslipidemialow density lipoprotein cholesterolhigh density lipoprotein cholesteroltotal cardiovascular risk calculationacute coronary syndromeReferencesESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217S :S1-S44.ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217S :S1-S44.Еuropean guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14 Suppl 2:E1-40.Еuropean guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14 Suppl 2:E1-40.Pencina M.J., Agostino R.B., Larson S.M. Predicting the 30-Year Risk of cardiovascular disease: The Framingham Heart Study. Circulation 2009;119:3078-84.Pencina M.J., Agostino R.B., Larson S.M. Predicting the 30-Year Risk of cardiovascular disease: The Framingham Heart Study. Circulation 2009;119:3078-84.Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35(2):139-51.Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35(2):139-51.Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract 2005;59(2):239-52.Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract 2005;59(2):239-52.Chang S.M., Yasbek N., Lakks N.M. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv 2004;62:193-7.Chang S.M., Yasbek N., Lakks N.M. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv 2004;62:193-7.Patti G., Pasceri V., Colonna G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Results of the ARMYDAACS Randomized Trial. J Am Coll Cardiol 2007;49:1272-8.Patti G., Pasceri V., Colonna G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Results of the ARMYDAACS Randomized Trial. J Am Coll Cardiol 2007;49:1272-8.Di Sciascio G., Patti G., Pasceri V., et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009;54;558-65.Di Sciascio G., Patti G., Pasceri V., et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009;54;558-65.RSC, NSA, RSCR expert opinion to optimize of statin therapy in clinical practice. Ration Pharmacother Cardiol 2011; 7 (1): 107-9. Russian (Заключение экспертов ВНОК, НОА и РОСОКР по оптимиза-ции терапии статинами в клинической практике. Рациональная Фармакотерапия в Кардиологии 2011; 7(1):107-9).RSC, NSA, RSCR expert opinion to optimize of statin therapy in clinical practice. Ration Pharmacother Cardiol 2011; 7 (1): 107-9. Russian (Заключение экспертов ВНОК, НОА и РОСОКР по оптимиза-ции терапии статинами в клинической практике. Рациональная Фармакотерапия в Кардиологии 2011; 7(1):107-9).Lablanchea J.M., Leoneb A., Merkelyc B., et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein AI ratio in patients with acute coronary syndrome: Results of the CENTAURUS study. Arch Cardiovasc Dis 2010; 103:160-9.Lablanchea J.M., Leoneb A., Merkelyc B., et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein AI ratio in patients with acute coronary syndrome: Results of the CENTAURUS study. Arch Cardiovasc Dis 2010; 103:160-9.Zadionchenko VS, Shehyan GG, Shahray NB, et al. Effect of rosuvastatin on lipid metabolism, microcirculation and central hemodynamics in patients with acute coronary syndrome. Consilium Medicum 2011; 13 (5): 4-8. Russian (Задионченко В.С., Шехян Г.Г., Шахрай Н.Б. и др. Влияние розува-статина на липидный обмен, микроциркуляцию и показатели центральной гемодинамики у боль-ных с острым коронарным синдромом. Consilium Medicum 2011;13(5):4-8).Zadionchenko VS, Shehyan GG, Shahray NB, et al. Effect of rosuvastatin on lipid metabolism, microcirculation and central hemodynamics in patients with acute coronary syndrome. Consilium Medicum 2011; 13 (5): 4-8. Russian (Задионченко В.С., Шехян Г.Г., Шахрай Н.Б. и др. Влияние розува-статина на липидный обмен, микроциркуляцию и показатели центральной гемодинамики у боль-ных с острым коронарным синдромом. Consilium Medicum 2011;13(5):4-8).Otagiri К., Tsutsui H., Kumazaki S. Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome – analysis using integrated backscatter IVUS (ELAN Study). Circ J 2011;75:633-41.Otagiri К., Tsutsui H., Kumazaki S. Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome – analysis using integrated backscatter IVUS (ELAN Study). Circ J 2011;75:633-41.Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the ESC and the EACTS Developed with the special contribution of the EAPCI. Eur Heart J 2010;31: 2501-55.Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the ESC and the EACTS Developed with the special contribution of the EAPCI. Eur Heart J 2010;31: 2501-55.

The authors declare that there are no conflicts of interest present.